vs

Side-by-side financial comparison of Arbutus Biopharma Corp (ABUS) and ACCESS Newswire Inc. (ACCS). Click either name above to swap in a different company.

Arbutus Biopharma Corp is the larger business by last-quarter revenue ($10.7M vs $5.8M, roughly 1.9× ACCESS Newswire Inc.). Arbutus Biopharma Corp runs the higher net margin — 23.5% vs -9.9%, a 33.4% gap on every dollar of revenue. On growth, Arbutus Biopharma Corp posted the faster year-over-year revenue change (522.2% vs -0.5%). Over the past eight quarters, ACCESS Newswire Inc.'s revenue compounded faster (2.0% CAGR vs -13.2%).

Arbutus Biopharma Corporation is a publicly traded Canadian biopharmaceutical company with an expertise in liposomal drug delivery and RNA interference, and is developing drugs for hepatitis B infection.

PR Newswire is a distributor of press releases headquartered in Chicago. The service was created in 1954 to allow companies to electronically send press releases to news organizations, using teleprinters at first. The founder, Herbert Muschel, operated the service from his house in Manhattan for approximately 15 years. The business was eventually sold to Western Union and then United Newspapers of London. In December 2015, Cision Inc. announced it would acquire the company. On January 1, 2021...

ABUS vs ACCS — Head-to-Head

Bigger by revenue
ABUS
ABUS
1.9× larger
ABUS
$10.7M
$5.8M
ACCS
Growing faster (revenue YoY)
ABUS
ABUS
+522.7% gap
ABUS
522.2%
-0.5%
ACCS
Higher net margin
ABUS
ABUS
33.4% more per $
ABUS
23.5%
-9.9%
ACCS
Faster 2-yr revenue CAGR
ACCS
ACCS
Annualised
ACCS
2.0%
-13.2%
ABUS

Income Statement — Q2 FY2025 vs Q4 FY2025

Metric
ABUS
ABUS
ACCS
ACCS
Revenue
$10.7M
$5.8M
Net Profit
$2.5M
$-576.0K
Gross Margin
77.4%
Operating Margin
13.9%
-13.1%
Net Margin
23.5%
-9.9%
Revenue YoY
522.2%
-0.5%
Net Profit YoY
112.7%
94.4%
EPS (diluted)
$0.01
$-0.16

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ABUS
ABUS
ACCS
ACCS
Q4 25
$5.8M
Q3 25
$5.7M
Q2 25
$10.7M
$5.6M
Q1 25
$5.5M
Q4 24
$5.8M
Q3 24
$5.6M
Q2 24
$6.0M
Q1 24
$5.6M
Net Profit
ABUS
ABUS
ACCS
ACCS
Q4 25
$-576.0K
Q3 25
$-45.0K
Q2 25
$2.5M
$-475.0K
Q1 25
$5.4M
Q4 24
$-10.2M
Q3 24
$-466.0K
Q2 24
$7.0K
Q1 24
$-139.0K
Gross Margin
ABUS
ABUS
ACCS
ACCS
Q4 25
77.4%
Q3 25
74.6%
Q2 25
76.2%
Q1 25
78.0%
Q4 24
75.2%
Q3 24
75.0%
Q2 24
77.2%
Q1 24
75.1%
Operating Margin
ABUS
ABUS
ACCS
ACCS
Q4 25
-13.1%
Q3 25
-3.2%
Q2 25
13.9%
-4.4%
Q1 25
-12.4%
Q4 24
-245.8%
Q3 24
-10.7%
Q2 24
-8.8%
Q1 24
-15.5%
Net Margin
ABUS
ABUS
ACCS
ACCS
Q4 25
-9.9%
Q3 25
-0.8%
Q2 25
23.5%
-8.5%
Q1 25
98.4%
Q4 24
-175.0%
Q3 24
-8.3%
Q2 24
0.1%
Q1 24
-2.5%
EPS (diluted)
ABUS
ABUS
ACCS
ACCS
Q4 25
$-0.16
Q3 25
$-0.01
Q2 25
$0.01
$-0.12
Q1 25
$1.40
Q4 24
$-2.66
Q3 24
$-0.12
Q2 24
$0.00
Q1 24
$-0.04

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ABUS
ABUS
ACCS
ACCS
Cash + ST InvestmentsLiquidity on hand
$37.4M
$3.0M
Total DebtLower is stronger
$0
Stockholders' EquityBook value
$83.0M
$30.3M
Total Assets
$103.3M
$42.0M
Debt / EquityLower = less leverage
0.00×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ABUS
ABUS
ACCS
ACCS
Q4 25
$3.0M
Q3 25
$3.3M
Q2 25
$37.4M
Q1 25
Q4 24
$4.1M
Q3 24
Q2 24
Q1 24
Total Debt
ABUS
ABUS
ACCS
ACCS
Q4 25
Q3 25
Q2 25
$0
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
Stockholders' Equity
ABUS
ABUS
ACCS
ACCS
Q4 25
$30.3M
Q3 25
$30.8M
Q2 25
$83.0M
$30.7M
Q1 25
$30.9M
Q4 24
$25.2M
Q3 24
$35.3M
Q2 24
$35.4M
Q1 24
$35.2M
Total Assets
ABUS
ABUS
ACCS
ACCS
Q4 25
$42.0M
Q3 25
$44.0M
Q2 25
$103.3M
$45.6M
Q1 25
$47.3M
Q4 24
$50.6M
Q3 24
$61.7M
Q2 24
$62.8M
Q1 24
$64.4M
Debt / Equity
ABUS
ABUS
ACCS
ACCS
Q4 25
Q3 25
Q2 25
0.00×
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ABUS
ABUS
ACCS
ACCS
Operating Cash FlowLast quarter
$-15.7M
$258.0K
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
0.0%
0.0%
Cash ConversionOCF / Net Profit
-6.24×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ABUS
ABUS
ACCS
ACCS
Q4 25
$258.0K
Q3 25
$-582.0K
Q2 25
$-15.7M
$135.0K
Q1 25
$747.0K
Q4 24
$866.0K
Q3 24
$1.5M
Q2 24
$-190.0K
Q1 24
$986.0K
Free Cash Flow
ABUS
ABUS
ACCS
ACCS
Q4 25
Q3 25
$-590.0K
Q2 25
Q1 25
$735.0K
Q4 24
Q3 24
$1.5M
Q2 24
Q1 24
$970.0K
FCF Margin
ABUS
ABUS
ACCS
ACCS
Q4 25
Q3 25
-10.3%
Q2 25
Q1 25
13.4%
Q4 24
Q3 24
26.5%
Q2 24
Q1 24
17.4%
Capex Intensity
ABUS
ABUS
ACCS
ACCS
Q4 25
0.0%
Q3 25
0.1%
Q2 25
0.0%
0.0%
Q1 25
0.2%
Q4 24
0.0%
Q3 24
0.1%
Q2 24
0.0%
Q1 24
0.3%
Cash Conversion
ABUS
ABUS
ACCS
ACCS
Q4 25
Q3 25
Q2 25
-6.24×
Q1 25
0.14×
Q4 24
Q3 24
Q2 24
-27.14×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ABUS
ABUS

Segment breakdown not available.

ACCS
ACCS

Cost To Deliver Products$3.1M54%
Employee Costs$1.7M29%
Other$1.0M17%

Related Comparisons